Gadolinium-based contrast agents (GBCA) are commonly used to identify blood-brain-barrier disruption. Recent studies reported gadolinium deposition in deep gray matter (GM) structures, following serial injections of linear complexes of GBCA. While it is recognized that linear complexes of GBCA may lead to gadolinium retention in brain, macrocyclic GBCA should also be evaluated. In this study, we investigated the effect of serial macrocyclic GBCA injections in 92 Multiple Sclerosis patients followed during seven years. Our results did not show any significant signal intensity changes in deep GM structures, and particularly in the dentate nuclei and the globus pallidus.